ストックスクリーナーアプリを入手
13.31
0.23%
0.03
アフターアワーズ：
13.09
-0.22
-1.65%
前日終値:
$13.28
開ける：
$13.27
24時間の取引高:
122.12K
Relative Volume:
0.63
時価総額：
$289.80M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+0.64%
1か月 パフォーマンス:
-1.84%
6か月 パフォーマンス:
-4.38%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$12.78
$13.44
1週間の範囲:
$12.50
$13.63
52週間の値動き範囲:
$4.88
$19.58
Aardvark Therapeutics Inc Stock (AARD) Company Profile
名前
Aardvark Therapeutics Inc
セクター
電話
(858) 225-7696
住所
4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO
AARD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AARD
Aardvark Therapeutics Inc
|
13.31 | 289.15M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-23 | 開始されました | Oppenheimer | Outperform |
| 2025-12-12 | 開始されました | William Blair | Outperform |
| 2025-12-03 | 開始されました | Raymond James | Strong Buy |
| 2025-11-07 | 開始されました | BTIG Research | Buy |
| 2025-09-29 | 開始されました | Stifel | Buy |
| 2025-06-30 | 開始されました | H.C. Wainwright | Buy |
| 2025-03-10 | 開始されました | BofA Securities | Buy |
| 2025-03-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-03-10 | 開始されました | Morgan Stanley | Overweight |
| 2025-03-10 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Aardvark Therapeutics Inc (AARD) 最新ニュース
What AI ML Trends Might Elevate Advance Metering Technology Limiteds Stock ProspectsLong-Term Growth Stocks & Free Unstoppable Trading Performance - earlytimes.in
Aug Gainers: Will Aardvark Therapeutics Inc stock deliver consistent dividends2025 Momentum Check & Community Trade Idea Sharing Platform - moha.gov.vn
Aardvark Therapeutics prices $94M IPO at $16 per share - MSN
Critical Contrast: Aardvark Therapeutics (AARD) and The Competition - Defense World
Aardvark Therapeutics up 9% at $10.10 after Raymond James Strong Buy initiation - MSN
Aardvark Therapeutics (AARD) – Investment Analysts’ Recent Ratings Updates - Defense World
Aardvark Therapeutics initiated with an outperform at Oppenheimer - MSN
Oppenheimer initiates Aardvark Therapeutics stock with Outperform rating By Investing.com - Investing.com South Africa
Oppenheimer initiates Aardvark Therapeutics stock with Outperform rating - Investing.com India
Oppenheimer Initiates Coverage of Aardvark Therapeutics (AARD) with Outperform Recommendation - Nasdaq
Aardvark Therapeutics, Inc.(NasdaqGS: AARD) added to NASDAQ Biotechnology Index - marketscreener.com
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Is Aardvark Therapeutics Inc. stock attractive for hedge fundsTrade Analysis Summary & Risk Adjusted Buy/Sell Alerts - bolumsonucanavari.com
What risks investors should watch in Aardvark Therapeutics Inc. stockMarket Risk Report & AI Forecast for Swing Trade Picks - Улправда
Will Aardvark Therapeutics Inc. stock maintain dividend yieldJuly 2025 Sector Moves & Smart Money Movement Tracker - DonanımHaber
Can Aardvark Therapeutics Inc. stock attract ESG capital inflows2025 Market Trends & Fast Moving Stock Trade Plans - DonanımHaber
How resilient is Aardvark Therapeutics Inc. stock in market downturns2025 Market Sentiment & Technical Pattern Based Signals - Улправда
Insider Buying: Aardvark Therapeutics CEO, Secretary & Director Bought US$101k Of Shares - simplywall.st
HC Wainwright Has Negative Outlook for AARD FY2025 Earnings - Defense World
Aardvark Therapeutics (NASDAQ:AARD) CEO Tien-Li Lee Purchases 7,000 Shares - MarketBeat
Aardvark Therapeutics (NASDAQ:AARD) CFO Purchases $43,200.00 in Stock - MarketBeat
Insider Stock Purchases: December 13, 2025 - Quiver Quantitative
Analysts’ Top Healthcare Picks: Aardvark Therapeutics, Inc. (AARD), Eli Lilly & Co (LLY) - The Globe and Mail
William Blair initiates coverage on Aardvark Therapeutics stock with Outperform rating - Investing.com Canada
Sun Nelson, CFO, buys Aardvark Therapeutics shares worth $43,200 By Investing.com - Investing.com Nigeria
Insider Buying: Nelson Sun Acquires Additional Shares of Aardvar - GuruFocus
Lee Tien-Li, CEO of Aardvark, buys $101k in AARD stock - Investing.com Australia
Sun Nelson, CFO, buys Aardvark Therapeutics shares worth $43,200 - Investing.com
Aardvark Therapeutics Executives Increase Their Holdings - TradingView — Track All Markets
CFO Sun Buys 3,000 ($43.2K) Of Aardvark Therapeutics Inc [AARD] - TradingView — Track All Markets
William Blair Initiates Coverage of Aardvark Therapeutics (AARD) with Outperform Recommendation - Nasdaq
Aardvark's Hunger Suppressing Drug Candidate Could Potentially Address Massive $10 Billion Market: Analyst - Sahm
William Blair Initiates Aardvark Therapeutics With Outperform Rating - marketscreener.com
Aardvark Therapeutics: Innovative Therapies for PWS and Obesity with Significant Market Potential - TipRanks
Aardvark Therapeutics stock rises 13% on positive trial updates, BTIG maintains Buy By Investing.com - Investing.com South Africa
Aardvark Therapeutics’ Promising Progress and Market Potential: Analyst Recommends Buy - TipRanks
Aardvark Therapeutics stock rises 13% on positive trial updates, BTIG maintains Buy - Investing.com Canada
Raymond James reiterates Strong Buy on Aardvark Therapeutics stock with $47 target - Investing.com Nigeria
Raymond James reiterates Strong Buy on Aardvark Therapeutics stock with $47 target By Investing.com - Investing.com South Africa
Aardvark doses first Australian patient in phase 3 PWS hunger trial - Investing.com Nigeria
Aardvark Therapeutics Inc (AARD) 財務データ
Aardvark Therapeutics Inc (AARD) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
2.52%
0.07%
大文字化:
|
ボリューム (24 時間):